180 related articles for article (PubMed ID: 23092832)
1. Meta-analysis of the efficacy of amifostine in the prevention of cisplatin ototoxicity.
Duval M; Daniel SJ
J Otolaryngol Head Neck Surg; 2012 Oct; 41(5):309-15. PubMed ID: 23092832
[TBL] [Abstract][Full Text] [Related]
2. Protection of normal tissue from the cytotoxic effects of chemotherapy and radiation by amifostine: clinical experiences.
Capizzi RL; Oster W
Eur J Cancer; 1995; 31A Suppl 1():S8-13. PubMed ID: 7577096
[TBL] [Abstract][Full Text] [Related]
3. Amifostine for children with medulloblastoma treated with cisplatin-based chemotherapy.
Fisher MJ; Lange BJ; Needle MN; Janss AJ; Shu HK; Adamson PC; Phillips PC
Pediatr Blood Cancer; 2004 Dec; 43(7):780-4. PubMed ID: 15390300
[TBL] [Abstract][Full Text] [Related]
4. [Amifostine otoprotection to cisplatin ototoxicity: a guinea pig study using otoacoustic emission distortion products (DPOEA) and scanning electron microscopy].
Hyppolito MA; de Oliveira AA; Lessa RM; Rossato M
Braz J Otorhinolaryngol; 2005; 71(3):268-73. PubMed ID: 16446928
[TBL] [Abstract][Full Text] [Related]
5. Assessment of the protective effects of amifostine against cisplatin-induced toxicity.
Hussain AE; Blakley BW; Nicolas M; Balderston J
J Otolaryngol; 2003 Oct; 32(5):294-7. PubMed ID: 14974858
[TBL] [Abstract][Full Text] [Related]
6. Interventions for preventing neuropathy caused by cisplatin and related compounds.
Albers J; Chaudhry V; Cavaletti G; Donehower R
Cochrane Database Syst Rev; 2007 Jan; (1):CD005228. PubMed ID: 17253547
[TBL] [Abstract][Full Text] [Related]
7. Exploration of platinum-based dose-intensive chemotherapy strategies with amifostine (Ethyol).
Schuchter LM
Eur J Cancer; 1996; 32A Suppl 4():S40-2. PubMed ID: 8976821
[TBL] [Abstract][Full Text] [Related]
8. Amifostine does not protect against the ototoxicity of high-dose cisplatin combined with etoposide and bleomycin in pediatric germ-cell tumors: a Children's Oncology Group study.
Marina N; Chang KW; Malogolowkin M; London WB; Frazier AL; Womer RB; Rescorla F; Billmire DF; Davis MM; Perlman EJ; Giller R; Lauer SJ; Olson TA;
Cancer; 2005 Aug; 104(4):841-7. PubMed ID: 15999362
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of amifostine for protection against cisplatin-induced serious hearing loss in children treated for average-risk or high-risk medulloblastoma.
Gurney JG; Bass JK; Onar-Thomas A; Huang J; Chintagumpala M; Bouffet E; Hassall T; Gururangan S; Heath JA; Kellie S; Cohn R; Fisher MJ; Panandiker AP; Merchant TE; Srinivasan A; Wetmore C; Qaddoumi I; Stewart CF; Armstrong GT; Broniscer A; Gajjar A
Neuro Oncol; 2014 Jun; 16(6):848-55. PubMed ID: 24414535
[TBL] [Abstract][Full Text] [Related]
10. The potential of amifostine: from cytoprotectant to therapeutic agent.
Santini V; Giles FJ
Haematologica; 1999 Nov; 84(11):1035-42. PubMed ID: 10553165
[TBL] [Abstract][Full Text] [Related]
11. Administration of the cytoprotectant amifostine.
Lindemann K
Clin J Oncol Nurs; 1998 Jul; 2(3):101-4. PubMed ID: 10232150
[TBL] [Abstract][Full Text] [Related]
12. Pharmacotherapeutic options for treating adverse effects of Cisplatin chemotherapy.
Santabarbara G; Maione P; Rossi A; Gridelli C
Expert Opin Pharmacother; 2016; 17(4):561-70. PubMed ID: 26581586
[TBL] [Abstract][Full Text] [Related]
13. High-dose Cisplatin with amifostine: ototoxicity and pharmacokinetics.
Ekborn A; Hansson J; Ehrsson H; Eksborg S; Wallin I; Wagenius G; Laurell G
Laryngoscope; 2004 Sep; 114(9):1660-7. PubMed ID: 15475801
[TBL] [Abstract][Full Text] [Related]
14. Amifostine protects against cisplatin-induced nephrotoxicity in a child with medulloblastoma.
Hayek M; Srinivasan A
Pediatr Hematol Oncol; 2003; 20(3):253-6. PubMed ID: 12637222
[No Abstract] [Full Text] [Related]
15. Prevention of cisplatin-induced ototoxicity in children and adolescents with cancer: a clinical practice guideline.
Freyer DR; Brock PR; Chang KW; Dupuis LL; Epelman S; Knight K; Mills D; Phillips R; Potter E; Risby D; Simpkin P; Sullivan M; Cabral S; Robinson PD; Sung L
Lancet Child Adolesc Health; 2020 Feb; 4(2):141-150. PubMed ID: 31866182
[TBL] [Abstract][Full Text] [Related]
16. Amifostine.
Viele C
Clin J Oncol Nurs; 1999 Jul; 3(3):128, 131. PubMed ID: 10690046
[No Abstract] [Full Text] [Related]
17. Transtympanic Ringer's lactate application in the prevention of cisplatinum-induced ototoxicity in a chinchilla animal model.
Munguia R; Sahmkow SI; Funnell WR; Daniel SJ
Otolaryngol Head Neck Surg; 2010 Jul; 143(1):134-40. PubMed ID: 20620632
[TBL] [Abstract][Full Text] [Related]
18. Effects of amifostine on acute toxicity from concurrent chemotherapy and radiotherapy for inoperable non-small-cell lung cancer: report of a randomized comparative trial.
Komaki R; Lee JS; Milas L; Lee HK; Fossella FV; Herbst RS; Allen PK; Liao Z; Stevens CW; Lu C; Zinner RG; Papadimitrakopoulou VA; Kies MS; Blumenschein GR; Pisters KM; Glisson BS; Kurie J; Kaplan B; Garza VP; Mooring D; Tucker SL; Cox JD
Int J Radiat Oncol Biol Phys; 2004 Apr; 58(5):1369-77. PubMed ID: 15050312
[TBL] [Abstract][Full Text] [Related]
19. Toxicity prevention with amifostine in pediatric osteosarcoma patients treated with cisplatin and doxorubicin.
Gallegos-Castorena S; Martínez-Avalos A; Mohar-Betancourt A; Guerrero-Avendaño G; Zapata-Tarrés M; Medina-Sansón A
Pediatr Hematol Oncol; 2007 Sep; 24(6):403-8. PubMed ID: 17710657
[TBL] [Abstract][Full Text] [Related]
20. Ototoxicity: bioprotective mechanisms.
Rybak LP; Kelly T
Curr Opin Otolaryngol Head Neck Surg; 2003 Oct; 11(5):328-33. PubMed ID: 14502062
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]